{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T04:23:30Z","timestamp":1767846210029,"version":"3.49.0"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EJR"],"abstract":"<jats:p>Abstract\n\tObjective: The aim of this study is to determine the incidence of isoniazid (INH)-related hepatotoxicity in patients with rheumatologic diseases receiving tumor necrosis factor-\u03b1 (TNF-\u03b1) antagonists along with a disease-modifying antirheumatic drug (DMARD).\n\n\t\u00a0\n\n\tMaterial and Methods: We have retrospectively evaluated 87 patients receiving anti-TNF\u03b1 agents who were followed up between June 2005 and February 2010 at our rheumatology department. Sixty-one of 87 patients have received INH prophylaxis for 9 months for latent tuberculosis infection. \n\n\t\u00a0\n\n\tResults: A total of 61 (70.1%) of 87 patients used INH prophylaxis (Group I), while the remaining 26 (29.9%) (Group II) had not; 53 patients had used any DMARD in Group I, while 21 patients had used in Group II. No significant differences were found among Group I and II with respect to clinical features. When two groups were compared, in Group I, elevations of liver enzymes were detected in five patients (8.1%) who had normal baseline values. Among these patients, hepatotoxicity developed in two patients. Hepatotoxicity developed one patient in Group II (p=0.85).\n\n\t\u00a0\n\n\tConclusion: INH chemoprophylaxis was well tolerated in patients using anti-TNF-\u03b1 agent and a DMARD. It seems not to be a strong risk factor for hepatotoxicity. However, comorbidities and other drugs used may be additional factors in the elevation of transaminases.\n\n\t\u00a0<\/jats:p>","DOI":"10.5152\/eurjrheumatol.2014.019","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T09:30:28Z","timestamp":1402997428000},"page":"62-66","source":"Crossref","is-referenced-by-count":4,"title":["Does isoniazid chemoprophylaxis increase the frequency of hepatotoxicity in patients receiving anti-TNF-\u03b1 agent with a disease-modifying antirheumatic drug?"],"prefix":"10.5152","volume":"1","author":[{"given":"D\u00f6nd\u00fc \u00dcsk\u00fcdar","family":"Cansu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabri","family":"G\u00fcncan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N. \u015eule","family":"Ya\u015far Bilge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timu\u00e7in","family":"Ka\u015fifo\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cengiz","family":"Korkmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3111","published-online":{"date-parts":[[2019,9,3]]},"container-title":["European Journal of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/download\/17\/17","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:30:35Z","timestamp":1753774235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/view\/17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,3]]},"references-count":0,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2019,9,3]]}},"URL":"https:\/\/doi.org\/10.5152\/eurjrheumatol.2014.019","relation":{},"ISSN":["2148-4279"],"issn-type":[{"value":"2148-4279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,3]]}}}